共查询到20条相似文献,搜索用时 15 毫秒
1.
Flis V Kobilica N Bergauer A Mrdža B Milotič F Štirn B 《The Journal of international medical research》2011,39(3):1107-1112
For various reasons some patients are unable to undergo intra-arterial thrombolysis for acute limb ischaemia. This interventional case series study prospectively evaluated the effect of thrombolytic treatment with 100 mg recombinant tissue plasminogen activator (rt-PA), administered intravenously, in patients with acute thrombosis of the lower limb arteries and onset of symptoms within 12 h prior to treatment. During a 3-year period (2007-2009), 18 of 86 patients satisfied the inclusion criteria and were included in the study (age range 65-80 years; 11 women). Complete and partial thrombolysis was observed in eight (44.4%) and six (33.3%) patients, respectively. All patients experienced clinical improvement. There were no amputations during the 36-month follow-up period and no haemorrhagic complications in the first 30 days post-treatment. Five patients died (27.8%) during follow-up from unrelated causes. This small study demonstrated that thrombolytic treatment with intravenous rt-PA in selected patients with acute limb ischaemia is feasible. 相似文献
2.
艾通立早期静脉溶栓治疗急性脑梗死--附100例病例分析 总被引:4,自引:0,他引:4
目的:评价重组组织型纤溶酶原激活剂(rt-PA)艾通立对急性脑梗死早期静脉溶栓治疗的疗效及安全性,同时探讨国人应用rt-PA治疗的最佳剂量。方法:凡符合入选标准的患者随机分为A、B、C 3组,A组为rt-PA0.9mg/kg,B组为rt-PA 0.7mg/kg,C组作为对照组不用rt-PA。溶栓两组先将总量中的8mg静脉快速推入,剩余量在1h内用静脉泵输入,总量均不超过90mg。观察3组治疗后24h、90d神经功能缺损评分,及90d日常生活能力指数(Barthel),同时观察3组治疗后30d脑出血率及病死率。结果:A组溶栓后24h和90d治愈及显效率为41.18%和76.47%,90d Barthel指数为95~100分者占58.82%,30d脑出血率为8.82%,病死率为5.88%。B组溶栓后24h和90d治愈及显效率为39.39%和69.70%,90d Barthel指数为95~100分者占54.55%,30d脑出血率为9.09%,病死率为9.09%。C组治疗后24h和90d治愈及显效率为21.21%和30.30%,90d Barthel指数为95~100分者占21.21%,30d病死率为9.09%。90d溶栓组显效率(73.13%)明显高于对照组(30.30%,P=0.0017),严重致残率分别为13.43%和24.24%。结论:急性脑梗死静脉应用rt-PA溶栓治疗是安全有效的,国外0.9mg/kg的剂量也适用于国人。 相似文献
3.
BACKGROUND: In patients who are candidates for IV recombinant tissue plasminogen activator (rtPA) thrombolysis for the treatment of acute ischemic stroke, blood pressure (BP)-lowering therapy is sometimes needed for systolic BP >185 mm Hg or diastolic BP >110 mm Hg. However, there is vast uncertainty regarding the appropriate choice of an antihypertensive agent. CASE SUMMARY: A 68-year-old Algerian woman (height, 161 cm; weight, 68 kg; body mass index, 26 kg/m2) was admitted to the Cardiology Unit of Amiens University Hospital, Amiens, France, for the assessment of nonvalvular atrial fibrillation. She was prescribed furosemide 40 mg/d to treat a slight left cardiac insufficiency. On day 10 of admission, the patient developed left-sided weakness. Neurologic examination revealed left hemiparesis. A computed tomography scan of the head showed no abnormality. Approximately 90 minutes after onset of the neurologic deficit, the patient had a BP of 180/100 mm Hg in both arms, an irregular pulse >75 bpm, and normal heart sounds. The patient was transferred to the Neurovascular Unit. There were no cervical or femoral bruits in this patient. During neurologic examination, the patient was alert and showed no signs of major cognitive deficit. The neurologic examination did reveal, however, minor hemisphere syndrome with left spatial neglect. There was a left lower-facial paresis. Motor examination revealed normal bulk with diminished tone in the patient's left arm and leg. Although there were no physical signs of dehydration, laboratory results revealed moderate signs of dehydration (total protein, 91 g/L [indicating proteinemia]; sodium, 147 mmol [indicating hypernatremia]; and elevated hematocrit, 42.0%). Considering the diagnosis of ischemic stroke and the duration of the symptoms (<3 hours), IV rtPA was administered. Approximately 10 minutes after intravenous rtPA administration, the patient's BP was 210/110 mm Hg, and an IV bolus of urapidil (20 mg) was administered. Approximately 2 minutes following urapidil administration, the patient developed neurologic worsening indicated by left-sided hemiplegia. Her BP was 105/60 mm Hg. The IV rtPA was immediately discontinued and volume replacement was started for 20 minutes. IV rtPA was restarted after the patient remained hemodynamically stable (15 minutes after rtPA was restarted). Following intensive physiotherapy, the patient was discharged on anticoagulation with a favorable outcome. At her 6-month follow-up, the patient had fully recovered. CONCLUSION: We report a probable case of hypotension associated with IV bolus of urapidil administration during rtPA thrombolysis for acute ischemic stroke in an elderly patient also treated with diuretics. 相似文献
4.
目的 观察伴心房颤动的急性脑梗死患者使用重组组织型纤溶酶原激活物(rt-PA)静脉溶栓的疗效.方法 连续收集发病时间<4.5h的94例应用rt-PA静脉溶栓治疗的急性脑梗死患者,将64例无心房颤动患者作为非心房颤动组,30例伴心房颤动患者作为心房颤动组,并收集同一时段30例未行溶栓治疗的伴有心房颤动的急性脑梗死患者作为对照组,比较3组患者治疗前及治疗后7d的美国国立卫生研究院卒中量表(NIHSS)评分,观察颅内出血(ICH)和症状性颅内出血(SICH)的发生率,采用改良Rankin量表(mRS)对3组患者3个月预后进行分析.结果 心房颤动组和非心房颤动组溶栓后7d的NIHSS评分较溶栓前显著降低(P<0.05或P<0.01);对照组治疗前后NIHSS评分比较差异无统计学意义(P>0.05);心房颤动组的ICH发生率高于非心房颤动组(26.7%vs.9.4%,P<0.05),而两组之间SICH发生率差异无统计学意义(13.3%vs.6.3%,P>0.05);心房颤动组、非心房颤动和对照组3个月预后良好的比例分别为40.0%、45.3%和16.7%,心房颤动组和非心房颤动组的3个月预后良好比例差异无统计学意义(P>0.05),均明显高于对照组(P<0.05或P<0.叭);心房颤动组、非心房颤动组和对照组预后极差的比例分别为20.0%、18.8%和33.3% (P >0.05).结论 伴有心房颤动的急性脑梗死患者rt-PA静脉溶栓治疗是安全有效的. 相似文献
5.
6.
A targetable, heparin-triggered release system for tissue plasminogen activator (tPA) was designed to prevent the excessive ‘lytic’ state associated with the current tPA therapy for acute thrombotic conditions, such as myocardial infarction (MI). The strategy is, upon target accumulation, to trigger tPA release from a prodrug construct by a usual heparin dose. A relatively inactive form of tPA was constructed by conjugating tPA with low-molecular weight heparin followed by complexation with albumin-protamine conjugate, termed ‘camouflage’. The modified tPA was ~ 97% as active as native tPA. The prodrug construct of tPA significantly masked the enzymatic activity, which was fully recovered upon heparin addition. The camouflaged tPA was stable in human blood for at least 30 min and was able to trigger enzyme activation in vitro at heparin level of 0.4 U/mL. In vivo studies on jugular vein rat thrombosis model showed that the clot lysis of the heparin-triggered camouflaged tPA group was equivalent to the tPA + heparin group without prolongation of activated partial thromboplastin time (aPTT) before and after the treatment. This proof-of-principle study suggests that the activity of the tPA prodrug construct can be triggered at the thrombus site at therapeutic heparin concentration conjunctively used for MI with reduced bleeding risk. 相似文献
7.
重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死19例 总被引:2,自引:0,他引:2
目的:评价重组组织型纤溶酶原激活剂(rtPA)静脉溶栓治疗急性脑梗死的疗效及预后相关因素.方法:选择发病6 h内的急性脑梗死患者38例,分为溶栓组和对照组(各19例),溶栓组采用rtPA 0.8 mg/ks静脉溶栓,对照组采用常规的活血化瘀营养脑细胞控制并发症治疗.进行两组患者治疗前,治疗后2 h、7 d、14 d、21 d、90 d的欧洲卒中神经功能缺损程度评分(ESS),以及治疗前、治疗后、7 d、14 d、21 d、90 d的Barthel指数评分比较.结果:随访90 d,溶栓组ESS评分和Barthel指数显著高于对照组,两组比较差异有显著性.结论:rtPA静脉溶栓治疗可使急性脑梗死患者神经功能缺损早期恢复,改善90 d的预后;治疗时间越早,溶栓效果越明显. 相似文献
8.
The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke 总被引:1,自引:0,他引:1
Kahn JH Viereck J Kase C Jeerakathil T Romero R Mehta SD Kociol R Babikian V 《The Journal of emergency medicine》2005,29(3):273-277
We sought to determine the frequency of use of intravenous (i.v.) recombinant tissue plasminogen activator (rt-PA) in patients presenting to our institution with acute ischemic stroke (AIS). This observational study involved keeping a log of all patients presenting to our institution with symptoms consistent with AIS who were potential candidates for emergency thrombolysis over a 3-year period. The log included brain computed tomography (CT) scan results, whether or not rt-PA was administered, and contraindications to thrombolysis. It also included each patient's time flow through the system, from symptom onset to decision time regarding (and administration of) thrombolytics. Over the 36-month period of the study, there were 142 patients who presented to the Emergency Department (ED) who initially were thought to be potential candidates for thrombolysis for AIS. Ninety-five (68.5%) of these 142 patients had a confirmed diagnosis of AIS. On further clarification of symptom onset, 77 (81%) of these 95 patients with AIS actually presented within 3 h, and 17 (22%) of these 77 patients met criteria for thrombolysis and had no contraindications. All 17 (100%) patients with AIS presenting within 3 h of onset and without contraindications received i.v. rt-PA in the ED. In conclusion, i.v. rt-PA can be administered for AIS within the 3-h window if a hospital is committed to providing this treatment. Thrombolysis remains a treatment for a minority of AIS patients. 相似文献
9.
10.
目的 探讨妇科盆腔术后并发下肢深静脉血栓形成(DVT)早期应用溶栓的疗效及安全性.方法 25例妇科盆腔术后并发早期下肢DVT患者随机分为抗凝治疗组(抗凝组13例)和溶栓治疗组[重组组织纤溶酶原激活剂(rt-PA)组12例].抗凝组予低分子肝素0.4 ml/d皮下注射,rt-PA组在此基础上一次性予rt-PA 100 mg经患肢静脉注射,7 d观察静脉再通率、凝血酶原时间(PT)及出血等不良并发症.结果 超声检查静脉rt-PA组复通率为91.7%(11/12),抗凝组为53.8%(7/13),2组差异有统计学意义(x2=15.68,P<0.01);2组各有1例发生阴道残端出血,未发现其他器官部位出血,2组出血率差异无明显统计学意义(x2=1.48,P>0.05),2例阴道残端出血患者均经局部止血后未再出血.结论 rt-PA用于妇科盆腔术后并发早期下肢.DVT的治疗,能有效提高下肢DVT静脉复通率,且不良反应较低.Abstract: Objective To explore the clinical effect and safety of using recombinant tissue type plasminogen activator (rt-PA) in early lower extremity deep venous thrombosis (DVT) after gynecological surgeries. Methods Twenty-five cases with early DVT after gynecological operation were enrolled and randomly divided into two groups,contorl group (n = 13) and the rt-PA therapy group (n = 12). The patients from contorl group were treated with Low-Molecular-Weight Heparins Calcium 0. 4 ml/d alone, and the rt-PA group accepted rt-PA 100 mg i. v in addition to the Low-Molecular-Weight Heparins Calcium. The recanalization rates of lamb veins,prothrombin time (PT) ,bleeding event and other adverse complications were observed and evaluated at day seven. Results The recanalization rates of lamb veins were 91. 7% (11/12) and 53. 8 % (7/13) in rtPA and the control group respectively,which showed significant difference between each other (x2 = 15. 68, P <0. 01). One case had vaginal stump bleeding in each group but no other hemorrhage in both group,the difference of bleeding rates between two groups didn't reach statistically significance (x2 = 1. 48 ,P> 0. 05). Two patients with vaginal stump bleeding were healed by local hemostasis. Conclusion The usage of rt-PA could improve the recanalization rate of DVT after gynecological surgery. The rates of adverse complications, including vaginal stump bleeding,were extremly low. 相似文献
11.
重组型纤溶酶原激活剂与尿激酶在急性心肌梗死溶栓中的比较 总被引:1,自引:0,他引:1
目的比较重组型纤溶酶原激活剂(rt—PA)和尿激酶(UK)对急性心肌梗死(AMI)溶栓的效果和不良反应。方法对我院AMI接受溶栓治疗患者回顾性分析,每组各30例,一组予70~100mgrt—PA溶栓,另一组予150万UUK溶栓治疗,统计两组溶栓再通率、不良反应发生率。其中48例择期行冠脉造影,以判定冠脉是否再通。同时与临床再通的指标进行比较。结果溶栓再通率rt—PA组为86.7%,UK组为63.3%,两组比较有统计学意义(P〈0.05);不良反应两组比较无统计学意义(P〉0.05);临床再通率与造影再通率正相关(r=0.90)。结论溶栓再通率rt—PA高于UK;判断临床再通率与造影再通率差异无统计学意义(P〉0.05),在没有冠脉造影的条件下,临床指标仍然是判定冠脉再通的有效指征。 相似文献
12.
目的 对比穿支动脉区孤立性梗死与其他类型脑梗死经静脉rtPA溶栓治疗后出血转化及神经功能结局的差异,明确穿支动脉区孤立性梗死静脉溶栓的安全性和有效性.方法 回顾分析了浙江大学医学院附属第二医院神经内科前瞻性收集的2009.06-2011.04期间接受静脉rtPA溶栓治疗的缺血性中风患者资料,包括性别、年龄、既往史、溶栓时间、基线NIHSS、血压、血糖、电解质、凝血谱、心电图、头颅MRI、颅内外MRA(或CTA)等,按照中国缺血性中风亚型(CISS)标准1予以病因分组.结果 共75例患者接受静脉rtPA治疗,年龄(67.4±12.7)岁,女性25例,占33.3%;溶栓前NIHSS(12.3±6.4)分;发病至溶栓时间:(239.6±97.5)min; 72例(96%)在24 h接受多模式MRI复查.共24例(32%)示溶栓后出血转化,4例(5.3%)为症状性出血.22例(29.3%)患者为穿支动脉区域孤立性梗死,仅1例(1.3%)发生出血转化.Logistic回归分析发现,穿支动脉区孤立性梗死明显降低溶栓后的出血转化风险(OR=0.075,95%CI:0.008~0.663; P=0.020).并发现,82%的穿支动脉区孤立性梗死患者的1月mRS评分≤2,其神经功能结局较其梗死好(P<0.01).结论 穿支动脉区域孤立梗死患者相对于其他类型脑梗死患者在经静脉rtPA溶栓治疗后,显示出更低的出血转化率和较好的神经功能结局,故对 此类患者的静脉溶栓治疗可更积极. 相似文献
13.
Ming Liu Hai-rong Wang Jia-fu Liu Hao-jun Li Shen-xing Chen Sha Shen Shu-ming Pan 《世界急诊医学杂志(英文)》2013,4(3):205-209
BACKGROUND:
The study aimed to compare the therapeutic effect of recombinant tissue plasminogen activator (rt-PA) on the onset of acute cerebral infarction (ACI) at different time points of the first 6 hours.METHODS:
A retrospective analysis was conducted in 74 patients who received rt-PA thrombolysis treatment within 4.5 hours after ACI and another 15 patients who received rt-PA thrombolysis treatment between 4.5–6 hours after ACI.RESULTS:
National Institute of Health Stroke Scale (NIHSS) scores were statistically decreased in both groups (P>0.05) at 24 hours and 7 days after ACI. There was no significant difference in modified ranking scores and mortality at 90 days after the treatment between the two groups (P>0.05).CONCLUSIONS:
The therapeutic effect and mortality of rt-PA treatment in patients with ACI between 4.5–6 hours after the onset of the disease were similar to those in patients who received rt-PA within 4.5 hours after the onset of this disease. Therefore, intravenous thrombolytic therapy for ACI within 4.5–6 hours after ACI was effective and safe.KEY WORDS: Acute cerebral infarction, Thrombolysis, Recombinant tissue type plasminogen activator 相似文献14.
目的:探讨重组组织型纤溶酶原激活剂(rtPA)超声增强溶栓联合强化降压治疗老年急性脑梗死(ACI)的临床效果及对预后转归的影响。方法:收集我院200例老年ACI患者,根据入院接受治疗时间分成对照组88例和观察组112例,对照组给予rtPA标准溶栓联合强化降压,观察组给予rtPA超声增强溶栓联合强化降压。记录两组血脂、神经功能及生活质量的变化,并对预后转归情况进行评价。结果:治疗后观察组总胆固醇(TC)、甘油三酯(TG)、卒中量表(NIHSS)评分低于对照组,巴塞尔指数(Barthel指数)高于对照组(P<0.05);观察组转归良好率及血管再通率高于对照组,出血转化率低于对照组(P<0.05)。结论:临床治疗以rtPA超声增强溶栓联合强化降压治疗为主,可有效改善老年ACI患者调脂效果及神经功能,还能提高转归良好率及血管再通率,对于促进生活能力的恢复也具有重要作用,值得临床推荐使用。 相似文献
15.
经胸廓内动脉置泵对急性心肌缺血犬t-PA和PAI的影响 总被引:1,自引:0,他引:1
目的 通过建立经胸廓内动脉置泵治疗犬急性心肌缺血的动物模型 ,观察介入组和对照组组织型纤溶酶原激活物及其抑制物 ( t PA、PAI)的变化。方法 6 0条健康杂种犬 ,随机分为介入组和对照组 ,每组 30条。在静脉麻醉下开胸 ,结扎左冠状动脉前降支 ,建立急性心肌缺血动物模型。介入组分离胸廓内动脉后远端结扎 ,在近端置管 ,外接输液加压泵 ,通过胸廓内动脉加压滴注硝酸甘油 ;对照组通过外周静脉滴注硝酸甘油。于冠状动脉结扎前、结扎后 0 .5 h、以及给予硝酸甘油 2 h和 6 h后股静脉采血测定 t PA和 PAI。结果 在冠状动脉结扎后 0 .5 h两组 t PA均升高 ,对照组在 2 h和 6 h逐渐下降 ,而介入组无明显变化 ;两组在结扎后 6 h差异有统计学意义 ( P<0 .0 5 )。冠状动脉结扎后两组 PAI逐渐上升 ,对照组在结扎后 6 h最高 ,而介入组在结扎后 2 h最高 ;两组 PAI在结扎后 6 h差异有统计学意义 ( P<0 .0 5 )。结论 经胸廓内动脉置泵介入治疗犬急性心肌缺血可促进血管内皮释放 t PA、抑制 PAI分泌 ,对纤溶平衡有一定的调节作用 相似文献
16.
Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.
下载免费PDF全文
![点击此处可从《The Journal of clinical investigation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
W Flameng F Van de Werf J Vanhaecke M Verstraete D Collen 《The Journal of clinical investigation》1985,75(1):84-90
Occlusive thrombus was produced by thrombin-induced coagulation in the left anterior descending coronary artery (LAD) of 16 open-chest baboons. In six control animals, occlusive thrombosis persisting over a period of 4 h as evidenced by coronary arteriography resulted in large transmural infarction (63.1 +/- 3.5% of the perfusion area). In 10 animals, tissue-type plasminogen activator obtained by recombinant DNA technology (rt-PA) was infused systemically at a rate of 1,000 IU (10 micrograms)/kg per min for 30 min after 30-80 min of coronary thrombosis. Reperfusion occurred within 30 min in nine animals. In one animal, intravenous infusion was followed by an intracoronary infusion at the same rate, which resulted in thrombolysis within 8 min. In the rt-PA group, mean duration of occlusion before reperfusion was 77 +/- 24 min. Reocclusion occurred in one animal. Recanalization resulted in an overall reduction of infarct size (37.8 +/- 5.9%, P less than 0.05 versus controls). Residual infarction was related to the duration of occlusion (r = 0.80, P less than 0.01). Reperfusion was associated with reduced reflow. Myocardial blood flow in the perfusion area of the LAD was only 70% of normal after 4 h despite perfect angiographic refilling. The infusion of rt-PA was not associated with systemic activation of the fibrinolytic system, fibrinogen breakdown, or clinically evident bleeding. It is concluded that intravenous infusion of rt-PA may recanalize thrombosed coronary vessels without inducing systemic lysis. The extent of residual infarction is closely related to the duration of coronary artery occlusion before thrombolysis. 相似文献
17.
重组人组织纤溶酶原激活剂治疗急性心肌梗死病人的护理 总被引:2,自引:2,他引:2
美国每年有 15 0万急性心肌梗死 (AMI)病人 ,总的病死率为 5 %~ 3 0 %。AMI是临床常见病 ,病死率极高。近几年我国AMI病人的人数也在快速上升。溶栓治疗是近年来治疗AMI的主要进展之一 ,它可限制梗死面积 ,改善预后 ,使AMI的病死率降低 2 0 %~ 2 5 % [1] 。重组人组织纤溶酶原激活剂(rt -PA )是一种糖蛋白 ,属第二代溶栓剂。我科自 2 0 0 2年 3月— 2 0 0 3年 7月对 2 6例有溶栓适应证且无禁忌证的AMI病人进行rt-PA溶栓治疗 ,现将其护理总结如下。1 临床资料及方法1.1 临床资料 2 0 0 2年 3月— 2 0 0 3年 7月 ,我科对 2 6例… 相似文献
18.
19.
重组组织型纤溶酶原激活物与尿激酶静脉溶栓治疗急性心肌梗死疗效比较 总被引:2,自引:0,他引:2
目的:观察小剂量(50mg)重组组织型纤溶酶原激活物(rtPA)与尿激酶(UK)静脉溶栓治疗急性心肌梗死的疗效。方法:将患者随机分为rtPA和UK2组进行对比研究。结果:rtPA组冠状动脉(冠脉)总再通率为75.0%,UK组冠脉总再通率为61.3%。患者在发病<3小时溶栓治疗,rtPA组冠脉再通率为86.7%,UK组冠脉再通率为66.7%,前者明显高于后者,但统计学处理尚无显著性差异(P>0.05),原因与例数较少有关;住院并发症和预后2组结果无明显差异,但平均CCU时间和平均住院时间前者〔(7.1±1.2)日和(22.5±6.1)日〕较后者〔(11.7±3.1)日和(27.3±7.3)日〕明显减少(P均<0.05)。结论:小剂量(50mg)rtPA有良好的溶栓效果,冠脉再通率高,尤其在发病后3小时内进行治疗效果更佳;rtPA溶栓无出血不良反应发生,并能显著缩短患者平均住院时间。 相似文献
20.
目的探讨黄芪注射液联合重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓对急性缺血性卒中患者的灌注CT检查结果以及脑梗死出血性转化(HT)发生的影响。方法对2013年5月至2014年7月因急性脑缺血性卒中发病6h内入院的54例患者进行回顾性分析,根据不同治疗方法分为rt-PA静脉溶栓治疗组(n=24)和黄芪注射液联合rt-PA组(n=30)两组。收集两组患者部分临床资料,并对所有患者溶栓前及溶栓后24h进行头部CT灌注检查计算出相对脑血流量(rCBF)、脑血容量(rCBV)、脑血管表面通透性(rPS)数值以及根据美国国立卫生研究院卒中量表(NIHSS)计算患者评分,另外收集2周内发生HT的患者例数,最后统计分析两组间治疗前后rCBF、rCBV、rPS、NIHSS评分的差值以及治疗2周内HT发生的病例数有无差别。结果黄芪注射液联合rt-PA组灌注CT参数的rCBF,CBV,rPS以及NIHSS评分治疗前后的差值均高于rt-PA组,差异有统计学意义(P0.05),但两组2周内HT的发生例数差异无统计学意义(P0.05)。结论黄芪注射液联合rt-PA能明显增加急性脑缺血卒中患者的脑部血流情况,同时减轻脑血管表面通透性,进而改善患者预后。 相似文献